The role of phosphatidylethanolamine-binding protein (PEBP) family in various diseases: Mechanisms and therapeutic potential

• Published in: Progress in biophysics and molecular biology Vol. 196; pp. 102 - 113
• Main Authors: Teng, Yeying, Xue, Haiping, Deng, Xiaoliang, Luo, Yanqun, Wu, Tao
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.06.2025
• Subjects: Animals; Cancer; Humans; Liver disease; Neoplasms - metabolism; Neoplasms - pathology; PEBP; Phosphatidylethanolamine Binding Protein - metabolism; Signal pathway; Signal Transduction; Signal pathway; PEBP; Liver disease; Cancer
• ISSN: 0079-6107; 1873-1732; 1873-1732
• DOI: 10.1016/j.pbiomolbio.2025.04.002

This article focuses on the phosphatidylethanolamine-binding protein (PEBP) family proteins, detailing PEBP1 and PEBP4 due to limited information on PEBP2 and PEBP3, in cellular signaling pathways and research in a spectrum of pathologies, including diverse cancers, metabolic disorders, immunological diseases and a subset of organ-specific diseases. It outlines the mechanisms through which PEBP1 and PEBP4 regulate essential signaling pathways that are critical for cellular processes such as proliferation, apoptosis, and metastasis. Recent advancements have shown further understanding of these proteins' roles in pathophysiology and their potential as future therapeutic targets. The findings suggest that the impact of PEBP1 and PEBP4 on the course of different diseases has underscored their potential for more in-depth medical research and novel clinically targeted therapies. [Display omitted] •Phosphatidylethanolamine-binding protein family is a crucial factor in disease cellular processes.•PEBP1 impacts diseases like cancer, metabolic disorders, and neurodegeneration via ERK/NF-κB inhibition.•PEBP4 promotes cancer cell survival and apoptosis resistance, with overexpression linked to tumor occurrence and metastasis.